Skip to main content
. 2020 Aug 6;16(8):e1008696. doi: 10.1371/journal.ppat.1008696

Fig 6. Differential effects of anti-TIM-3, anti-PD-1 and anti-CTLA-4 blocking antibodies on rescuing of the proliferative capacity of CD8+ T cells restricted by different HLA-alleles.

Fig 6

(A) Representative flow cytometry plots, and (B) cumulative data showing proliferation of antigen-specific CD8+ T cells restricted by non-HLA-B*27/B57 following stimulation with their cognate-epitopes in the absence or presence of anti-PD-1 (Pembrolizumab 5 μg/ml), anti-TIM-3 (10 μg/ml LEAF) antibodies for 96 hours as measured by CFSE dilution assay, QK9 (QVPLRPMTYK), patient #LNP04. (C) Representative flow cytometry plots, and (D) cumulative data showing proliferation of antigen-specific CD8+ T cells restricted by HLA-B*27/B57 following stimulation with their cognate-epitopes in the absence or presence of anti-PD-1 (Pembrolizumab 5 μg/ml), anti-TIM-3 (10 μg/ml LEAF) antibodies for 96 hours as measured by CFSE dilution assay, KF11 (KAFSPEVIPMF), patient #LNP04. (E) Representative flow cytometry plots, and (F) cumulative data showing proliferation of antigen-specific CD8+ T cells restricted by HLA-B*35Px following stimulation with their cognate-epitopes in the absence or presence of anti-PD-1 (Pembrolizumab 5 μg/ml), anti-TIM-3 (10 μg/ml LEAF) antibodies for 96 hours as measured by CFSE dilution assay, QM9 (QVTNSATIM), patient #PR05. (G) Representative flow cytometry plots, and (H) cumulative data showing proliferation of antigen-specific CD8+ T cells restricted by HLA-B*35Px following stimulation with their cognate-epitopes in the absence or presence of anti-CTLA-4 (Ipilimumab 5 μg/ml) antibody for 96 hours as measured by CFSE dilution assay, QM9 (QVTNSATIM), patient #PR05. (I) Representative flow cytometry plots showing proliferation of antigen-specific CD8+ T cells restricted by HLA-B*27 following stimulation with GY9 (GLNKIVRMY) epitope, and (J) CD8+ T cells restricted by HLA-A24 following stimulation with epitope RL9 (RYLKDQQLL) in the absence or presence of anti-CTLA-4 (Ipilimumab 5 μg/ml) antibody for 96 hours as measured by CFSE dilution assay, patient #LNP01. Each point represents data from an epitope.